BiCNU
(Carmustine)ApprovedSmall molecule
Carmustine is a chemotherapy drug used to treat certain cancers including brain tumors, lymphomas, and multiple myeloma by damaging cancer cell DNA and stopping them from growing.[2] BiCNU is currently approved and in use across 20 indications[4].[1]
BiCNU is one of 385 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Approved.
20
Indications
165
Total Trials
13
Active Trials
384
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 20 indications
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1BiCNU
MMelissa K Accordino
Approved
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma49 trials
Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
Completed·—·Phase 1·NCT00569985·5 enrolled
Show 46 more trials
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
Completed·—·Phase 2·NCT00695409·122 enrolled
High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma
Completed·—·N/A·NCT00544570·30 enrolled
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Terminated·—·Phase 1·NCT00003567·8 enrolled
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
Recruiting·—·Phase 2·NCT04871607·33 enrolled
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
Completed·—·Phase 1·NCT01476839·25 enrolled
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Active, not recruiting·—·Phase 1·NCT00641381·25 enrolled
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Suspended·—·Phase 2·NCT06692452·24 enrolled
Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma
Completed·—·Phase 2·NCT00028665·37 enrolled
Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Completed·—·Phase 2·NCT00559104·60 enrolled
Glioblastoma Multiforme11 trials
Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Withdrawn·—·Phase 2·NCT00046878
Show 8 more trials
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00086879·110 enrolled
Multiple Myeloma10 trials
Show 7 more trials
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
Completed·—·Phase 2·NCT00004072·17 enrolled
Malignant Glioma9 trials
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
Completed·—·Phase 1·NCT00002986·36 enrolled
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
Completed·—·Phase 1·NCT00002988·36 enrolled
Show 6 more trials
Glioma7 trials
Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain
Completed·—·Phase 1·NCT00003348·56 enrolled
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
Completed·—·Phase 2·NCT00005081
Show 4 more trials
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
Completed·—·Phase 2·NCT00003467·68 enrolled
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
Completed·—·Phase 1·NCT00003463
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00003176·82 enrolled
49 more indications
Diffuse Large B-Cell Lymphoma5 trials
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00242996·44 enrolled
Mantle Cell Lymphoma5 trials
Chronic Lymphocytic Leukemia4 trials
Show 1 more trial
Bone Marrow Transplantation4 trials
Stem Cell Transplant4 trials
Lymphoid Malignancies4 trials
Breast Cancer4 trials
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Withdrawn·—·Phase 1/2·NCT00006123
Show 1 more trial
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Unknown status·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2·NCT02670109·20 enrolled
Autologous Stem Cell Transplantation2 trials
Metastatic Melanoma2 trials
Leukemia2 trials
Cutaneous T-cell lymphoma2 trials
Brain Cancer2 trials
Radiation Therapy in Treating Patients With Brain Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002620·212 enrolled
Stem Cell Transplantation2 trials
Anaplastic Astrocytoma2 trials
Hematologic Malignancy1 trial
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Terminated·—·Phase 2·NCT01500161·1 enrolled
Refractory Solid Tumors1 trial
Metastatic Prostate Cancer1 trial
T-cell non-Hodgkin lymphoma1 trial
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
Completed·—·Phase 1·NCT02342782·20 enrolled
Hodgkin's Disease1 trial
Uveal Melanoma1 trial
Graft Versus Host Disease1 trial
Patients With Solid Tumors1 trial
O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors
Completed·—·Phase 1·NCT00002604·28 enrolled
Soft Tissue Sarcoma1 trial
Primary Brain Tumor1 trial
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Completed·—·Phase 1·NCT00003484·21 enrolled
Efficacy and Safety1 trial
HIV infection1 trial
Relapse1 trial
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
Terminated·—·Phase 3·NCT02366663·3 enrolled
Chronic Myelogenous Leukemia1 trial
Recurrent1 trial
Brain Neoplasm1 trial
Glioblastoma1 trial
Phase 21 trial
Metastatic Colorectal Cancer1 trial
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Completed·—·Phase 2·NCT00005981·13 enrolled
Induction Therapy1 trial
Acute Myeloid Leukemia1 trial
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002719·500 enrolled
Colorectal Cancer1 trial
Central Nervous System Cancer1 trial
Prophylaxis1 trial
Immunodeficiency1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
BICNU
NDA NDA017422
Sep 23, 1996
GLIADEL
NDA NDA020637
May 16, 2022
CARMUSTINE
NDA NDA215000
Sources
References
- [1]
- [2]MedlinePlus Drug Information — BiCNU drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Carmustine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glutathione Reductase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- MMelissa K Accordino